Webcast Alert: Oscient Pharmaceuticals Announces Date for Release
of Third Quarter Financial Results
WALTHAM, Mass., Nov. 1 /PRNewswire-FirstCall/ -- Oscient Pharmaceuticals
(NASDAQ:OSCI) will release financial results for the third quarter ended
September 25, 2004 on Tuesday, November 9, 2004 prior to the opening of the
U.S. financial markets. A conference call will be held at 9:00 a.m. Eastern
Time with Steven Rauscher, President and CEO, and other members of senior
management.
What: Third Quarter Financial Results When: November 9, 2004 at 9:00 am Eastern Time How: Domestic participants can access the call by dialing 1-888-634-
4009. International participants are asked to dial 1-706-634-
2285. The call will also be webcast through the Company's
website at http://www.oscient.com/.
Contact: Christopher Taylor, 781-398-2466 or Sarah Emond, 781-398-2544 A replay will be available two hours after the conclusion of the call until
November 16. Domestic participants can access the replay by dialing 1-
800-642-1687, while international participants are asked to dial 1-706-645-
9291. The conference ID number for the replay is 1986067. A replay will also
be available through http://www.oscient.com/.
About Oscient Pharmaceuticals Oscient Pharmaceuticals Corporation is a biopharmaceutical company committed to
the clinical development and commercialization of novel therapeutics to address
unmet medical needs. The Company is marketing FACTIVE(R) (gemifloxacin
mesylate) tablets, approved by the FDA for the treatment of acute bacterial
exacerbations of chronic bronchitis and community-acquired pneumonia of mild to
moderate severity. In addition to the oral tablet form, Oscient
Pharmaceuticals is developing an investigational FACTIVE intravenous
formulation for use in hospitalized patients.
The Company has a novel antibiotic candidate, Ramoplanin, in advanced clinical
development for the treatment of Clostridium difficile-associated diarrhea
(CDAD). The Company's preclinical program includes an oral peptide deformylase
(PDF) inhibitor series, under preclinical development for community-based
respiratory tract infections. DATASOURCE: Oscient Pharmaceuticals CONTACT: Christopher Taylor, +1-781-398-2466 or Sarah Emond, +1-781-398-2544, both of Oscient Pharmaceuticals Web site: http://www.oscient.com/
|